8 April 2020

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

2020-04-08T17:35:43-07:00

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC);

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research2020-04-08T17:35:43-07:00
8 April 2020

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer

2020-04-08T16:31:07-07:00

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer2020-04-08T16:31:07-07:00
Go to Top